Lacidipine Tablets

1. Pharmacological action: This product is a dihydropyridine calcium ion antagonist, which is highly selective for calcium channels in smooth muscles, mainly dilates peripheral arteries, reduces peripheral resistance, and has a strong and lasting antihypertensive effect. It has no significant effect on the cardiac conduction system and myocardial contractile function. It can also improve the diastolic function of damaged hypertrophic left ventricle and have anti-atherosclerotic effects. It can increase renal blood flow without affecting the glomerular filtration rate, and can produce transient but not obvious diuretic and natriuretic effects, so it can prevent cyclosporine A-induced renal hypoperfusion in transplant patients. This product is highly lipid-soluble, it is deposited in the lipid part and continuously released to the binding site during the clearance stage. This feature makes this product significantly different from other calcium antagonists, which have low lipid solubility and therefore short action time. 2. Toxicological effects: Acute, subacute and chronic toxicological studies on Sparague-Dawley rats and Beagle dogs for 78 weeks showed that the maximum repeated dose was 32 mg/kg (1 month) or 20 mg/kg (6 months) for rats and 8.5 mg/kg (1 month) or 5 mg/kg (6 months) for dogs. Changes related to the efficacy of this product include tachycardia and constipation. A 60-week oral toxicity study in dogs showed that gingival hyperplasia could be found in the highest dose group (1 mg/kg and 5 mg/kg). Carcinogenicity, teratogenicity and mutagenicity: The drug was found to have no carcinogenicity, teratogenicity or mutagenicity through research.

Lacidipine The chemical name of lacidipine is: (±)-2,6-dimethyl-4-2-[(E)-2-(tert-butyloxycarbonyl)-vinyl]phenyl-1,4-dihydro-3,5-pyridinedicarboxylic acid diethyl ester. Molecular formula: C26H33NO6. Molecular weight: 455.6.

This product is white flakes, odorless and tasteless, and unstable when exposed to light.

hypertension.

The starting dose for adults is 4 mg, once a day, preferably in the morning. It can be taken before or after meals. If necessary, it can be increased to 6 mg or 8 mg once a day in 3-4 weeks. Unless the clinical need is more urgent and the drug is administered earlier. The initial dose for patients with liver disease is 2 mg, once a day.

The most common symptoms are headache, skin flushing, edema, dizziness and palpitations. Rare symptoms include weakness, rash (including erythema and itching), poor appetite, nausea, polyuria. Very few patients have chest pain and gingival hyperplasia.

People who are allergic to the ingredients of this product.

Precautions for children: This product has no experience in children. Precautions for pregnancy and lactation: 1. There is no data to prove the safety of this product for human pregnancy. Pregnant women should weigh the pros and cons. 2. This product and its metabolites are excreted in breast milk. It is best not to breastfeed or stop using this product. 3. This product may cause uterine muscle relaxation. Women in labor should use it with caution. Precautions for the elderly: The initial dose for the elderly is 2 mg, once a day. If necessary, it can be increased to 4 mg and 6 mg, once a day. It can be taken continuously for a long time.

1. When used in combination with beta-blockers and diuretics, the antihypertensive effect can be enhanced. 2. When used in combination with cimetidine, the blood concentration of this product can be increased. 3. When used in combination with digoxin, the peak level of digoxin can be increased by 17%, and there is no effect on the 24-hour average digoxin level. 4. When used in combination with propranolol, the area under the drug-time curve (AUC) of both can be slightly increased. 5. There is no special cross reaction with warfarin, tolbutamide, diclofenac, cyclosporine, antipyrine, etc.

Keep away from light and store in sealed container.

4 mg; 4 mg

24 months

Harbin Pharmaceutical Group Sanjing Mingshui Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-30

• Address:

  Sanjing Pharmaceutical Industrial Park, Mingshui County, Suihua City, Heilongjiang Province

• Tax NO.:

  91231225726919956Y

• Registered Funds:

  40 million yuan

• Email:

  Log in to view